Redeye updates its estimates and valuation of Sdiptech following the Q3 2025 report. The underlying financial performance was relatively undramatic, and we consider the quarter's key takeaways to be the new information on the planned divestments of non-core subsidiaries and the revised target for 2025e acquired EBITA. We make minor changes to our estimates and valuation, mostly related to taking a slightly more conservative stance on the divestment process and the near-term acquisition pace.

Read more and download the Research Update.
 
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
 
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/